WO2002092627A3 - Use of casb 7439 for treatment and diagnosis of lung cancer - Google Patents

Use of casb 7439 for treatment and diagnosis of lung cancer Download PDF

Info

Publication number
WO2002092627A3
WO2002092627A3 PCT/EP2002/005011 EP0205011W WO02092627A3 WO 2002092627 A3 WO2002092627 A3 WO 2002092627A3 EP 0205011 W EP0205011 W EP 0205011W WO 02092627 A3 WO02092627 A3 WO 02092627A3
Authority
WO
WIPO (PCT)
Prior art keywords
lung cancer
carcinoma
diagnosis
treatment
casb
Prior art date
Application number
PCT/EP2002/005011
Other languages
French (fr)
Other versions
WO2002092627A2 (en
Inventor
Thierry Coche
Swann Romain Jean-Thoma Gaulis
Y De Bassols Carlotta Vinals
Original Assignee
Glaxosmithkline Biolog Sa
Thierry Coche
Swann Romain Jean-Thoma Gaulis
Y De Bassols Carlotta Vinals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa, Thierry Coche, Swann Romain Jean-Thoma Gaulis, Y De Bassols Carlotta Vinals filed Critical Glaxosmithkline Biolog Sa
Priority to AU2002342250A priority Critical patent/AU2002342250A1/en
Publication of WO2002092627A2 publication Critical patent/WO2002092627A2/en
Publication of WO2002092627A3 publication Critical patent/WO2002092627A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The use of CASB7439 polypeptides and polynucleotides, and variants, immunogenic fragments and fusions thereof, and of immunogenic compositions thereof, in the prophylaxis, treatment and diagnosis of preneoplasic lesions of lung cancer and lung cancer, for instance SCLC, or NSCLC such as squamous (epidermoid) carcinoma, adenocarcinoma (including bronchoalveolar) and large cell (undifferentiated) carcinoma (including bronchoalveolar) and large cell (undifferentiated) carcinoma; or carcinoids, or bronchial gland tumours or mesotheliomas is disclosed. Methods of diagnosing the presence of preneoplasic lesions of lung cancer and lung cancer, in a subject related to the expression or activity of a CASB7439 polynucleotide or polypeptide are also disclosed.
PCT/EP2002/005011 2001-05-16 2002-05-07 Use of casb 7439 for treatment and diagnosis of lung cancer WO2002092627A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002342250A AU2002342250A1 (en) 2001-05-16 2002-05-07 Use of casb 7439 for treatment and diagnosis of lung cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0111974.2A GB0111974D0 (en) 2001-05-16 2001-05-16 Novel Compounds
GB0111974.2 2001-05-16

Publications (2)

Publication Number Publication Date
WO2002092627A2 WO2002092627A2 (en) 2002-11-21
WO2002092627A3 true WO2002092627A3 (en) 2003-02-06

Family

ID=9914758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/005011 WO2002092627A2 (en) 2001-05-16 2002-05-07 Use of casb 7439 for treatment and diagnosis of lung cancer

Country Status (3)

Country Link
AU (1) AU2002342250A1 (en)
GB (1) GB0111974D0 (en)
WO (1) WO2002092627A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA020617B1 (en) * 2009-05-27 2014-12-30 Глаксосмитклайн Байолоджикалс С.А. Casb7439 constructs

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004187A2 (en) * 1998-07-14 2000-01-27 The Johns Hopkins University Methods and kits for diagnosing and determination of the predisposition of diseases
WO2001002828A2 (en) * 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
WO2001062778A2 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Biologicals S.A. Tumour-specific animal proteins
WO2002066506A2 (en) * 2001-02-21 2002-08-29 Glaxosmithkline Biologicals S.A. Use of casb7439 (ash2) in the immunotherapy of breast cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000004187A2 (en) * 1998-07-14 2000-01-27 The Johns Hopkins University Methods and kits for diagnosing and determination of the predisposition of diseases
WO2001002828A2 (en) * 1999-07-07 2001-01-11 Tularik Inc. Diagnosis of cancer by detecting ash2 polypeptides or polynucleotides
WO2001062778A2 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Biologicals S.A. Tumour-specific animal proteins
WO2002066506A2 (en) * 2001-02-21 2002-08-29 Glaxosmithkline Biologicals S.A. Use of casb7439 (ash2) in the immunotherapy of breast cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ALDERS M ET AL: "The human Achaete-Scute homologue 2 (ASCL2, HASH2) maps to chromosome 11p15.5, close to IGF2 and is expressed in extravillus trophoblasts", HUMAN MOLECULAR GENETICS, OXFORD, GB, vol. 6, no. 6, 1997, pages 859 - 867, XP002173709, ISSN: 0964-6906 *
CHEN HERBERT ET AL: "Conservation of the Drosophila lateral inhibition pathway in human lung cancer: A hairy-related protein (HES-1) directly represses achaete-scute homolog-1 expression", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, WASHINGTON, US, vol. 94, no. 10, May 1997 (1997-05-01), pages 5355 - 5360, XP002180770, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
AU2002342250A1 (en) 2002-11-25
GB0111974D0 (en) 2001-07-04
WO2002092627A2 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
EP1272636B8 (en) A gene differentially expressed in breast and bladder cancer and encoded polypeptides
WO2002013847A3 (en) Methods for diagnosis and therapy of hematological and virus-associated malignancies
WO2001051633A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2001092523A3 (en) Human polynucleotides and polypeptides encoded thereby
WO2002004514A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2000058473A3 (en) Nucleic acids including open reading frames encoding polypeptides; 'orfx'
BR0112542A (en) Compositions and methods for ovarian cancer therapy and diagnosis
WO1997044461A3 (en) Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
WO2001082961A3 (en) Methods for treating bone tumors
WO2005046722A3 (en) Carbohydrate antigen-nanoparticle conjugates and uses thereof as antimetastatic agents in treating cancer
PL320964A1 (en) Chemical compounds
WO2002092627A3 (en) Use of casb 7439 for treatment and diagnosis of lung cancer
WO2001083739A3 (en) Human pellino polypeptides
WO2001049729A3 (en) Novex polypeptides, nucleic acids encoding same and their diagnostic and therapeutic use
WO2002066506A3 (en) Use of casb7439 (ash2) in the immunotherapy of breast cancer
WO2003086175A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
ATE108188T1 (en) LAMININ BINDING PEPTIDE FRAGMENTS.
DE69033810T2 (en) PRODUCTION AND USE OF THE HUMAN NM23-H2 PROTEIN AND ANTIBODIES AGAINST IT
MX9805299A (en) Novel polynucleotides panc1a and panc1b associated with pancreatic cancer.
WO2001055391A3 (en) 84p2a9: a prostate and testis specific protein highly expressed in prostate cancer
WO2002098913A3 (en) Polypeptides and corresponding polynucleotides for prophylaxis and treatment of colon cancer
WO2003016344A3 (en) Use of lung carcinoma antigen
EP1363929A4 (en) Compositions and methods for the therapy and diagnosis of breast cancer
LAUDADIO et al. Mucoepidermoid tumour of the parotid gland: a very difficult prognostic evaluation
EP0974664A3 (en) Human polypeptides and polynucleotides homolog to mouse testes-specific angiotensins converting enzyme

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP